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Purpose: Elevated postprandial glycaemia [PPG] increases the risk of cardiometabolic
complications in insulin-resistant, centrally obese individuals. Therefore, strategies
that improve PPG are of importance for this population. Consuming large doses of
whey protein [WP] before meals reduces PPG by delaying gastric emptying and
stimulating the secretion of the incretin peptides, glucose-dependent insulinotropic
polypeptide [GIP] and glucagon-like peptide 1 [GLP-1]. It is unclear if these effects are
observed after smaller amounts of WP and what impact central adiposity has on these
gastrointestinal processes.
Methods: In a randomised-crossover design, 12 lean and 12 centrally obese adult males
performed two 240 min mixed-meal tests, ~5–10 d apart. After an overnight fast,
participants consumed a novel, ready-to-drink WP shot (15 g) or volume-matched
water (100 ml; PLA) 10 min before a mixed-nutrient meal. Gastric emptying was
estimated by oral acetaminophen absorbance. Interval blood samples were collected to
measure glucose, insulin, GIP, GLP-1, and acetaminophen.
Results: WP reduced PPG area under the curve [AUC0–60] by 13 and 18.2% in the
centrally obese and lean cohorts, respectively (both p <0.001). In both groups, the
reduction in PPG was accompanied by a two-three-fold increase in GLP-1 and delayed
gastric emptying. Despite similar GLP-1 responses during PLA, GLP-1 secretion during
theWP trial was ~27% lower in centrally obese individuals compared to lean (p = 0.001). In
lean participants, WP increased the GLP-1ACTIVE/TOTAL ratio comparative to PLA (p =
0.004), indicative of reduced GLP-1 degradation. Conversely, no treatment effects for
GLP-1ACTIVE/TOTAL were seen in obese subjects.
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Conclusion: Pre-meal ingestion of a novel, ready-to-drink WP shot containing just 15 g of
dietary protein reduced PPG in lean and centrally obese males. However, an attenuated
GLP-1 response to mealtime WP and increased incretin degradation might impact the
efficacy of nutritional strategies utilising the actions of GLP-1 to regulate PPG in centrally
obese populations. Whether these defects are caused by an individual’s insulin
resistance, their obese state, or other obesity-related ailments needs further investigation.
Clinical Trial Registration: ISRCTN.com, identifier [ISRCTN95281775]. https://www.
isrctn.com/.
Keywords: gastric emptying, GLP-1 - glucagon-like peptide-1, whey protein, metabolic syndrome, GIP - glucose-
dependent insulinotropic peptide, central obesity, incretin peptides, postprandial glycaemia
INTRODUCTION
The prevalence of obesity is increasing globally, which poses a
significant challenge to health care systems. Obesity is a well-
defined risk factor for the development of cardio-metabolic
complications such as cardiovascular disease [CVD] and type 2
diabetes [T2D] (1, 2). In fact, obesity increases the risk of T2D
six-fold, irrespective of genetic risk (3). Yet not all obese
individuals develop T2D or display dysglycaemia. Instead, fat
distribution is a critical determinant of insulin sensitivity (4),
specifically when fat is stored around visceral areas (5–7), which
is associated with hepatic insulin resistance, dyslipidaemia and
impairments in insulin-mediated peripheral glucose disposal (8).
In the years that precede the transition from normal glucose
tolerance [NGT] to T2D, a progressive decline in both insulin’s
action and its secretion occurs augmenting a steady decline in
glucose tolerance (9). For individuals who develop T2D, evidence
suggests that it is the deterioration in postprandial glycaemia [PPG],
rather than fasting glycaemia, that precedes the decline to overt
dysglycaemia (10). Notably, PPG excursions have been shown to
independently predict future cardiovascular morbidity and
mortality even when fasting blood glucose concentrations or
HbA1c are normalised (11–13). Therefore, approaches to
minimising PPG are of importance for both patient and non-
patient populations.
Several lines of work demonstrate that mealtime whey protein
[WP] supplementation may serve as a simple, non-
pharmaceutical approach to improve PPG control [as reviewed
(14)]. WP is rich in branched-chain amino acids and bioactive
peptides [potentially b-lactoglobulin and a-lactalbumin (15)]
that upon digestion are rapidly absorbed into circulation. These
constituents are potent insulin secretagogues (16) that also
augment the incretin effect through the release of incretin
peptides, glucose-dependent insulinotropic polypeptide [GIP]
and glucagon-like peptide 1 [GLP-1] (15, 17), and delay the
rate of gastric emptying (18). However, where a wealth of
evidence demonstrates that pre-meal WP supplementation
attenuates glycaemic excursions in obese individuals with T2D
(19–23), studies investigating this treatment in obese subjects
without overt dysglycaemia are scarce (24). This is surprising
given such populations are likely exposed to periods of
postprandial hyperglycaemia (25) and are at an increased risk
of CVD and T2D (1, 2). There is also evidence to suggest that
obese individuals have reduced gastrointestinal sensitivity to
dietary nutrients (26–28), which may compromise the
effectiveness of dietary preloads to regulate PPG. However, the
gastrointestinal responses to mealtime WP in obese individuals
remain poorly characterised.
Clinically meaningful improvements in metabolic health require
chronic changes in PPG and other cardio-metabolic markers (29). It
is, therefore, imperative to consider the long-term application of an
available treatment and its sustainability to improve metabolic
health. To this end, there are several methodological limitations
associated with mealtime WP supplementation that have not been
addressed in previous studies (14). For instance, it is common
practice to present WP preloads as unpalatable, dry-mix powders
that require dilution and mixing with flavouring immediately prior
to their consumption (20–22, 24). However, there is a general
unwillingness to consume dry-mix protein supplements in the
presence of others (30) with taste and convenience also
determining eating behaviours (31). These observations suggest
that current preloading strategies are unlikely to be applicable
beyond the research setting.
Accordingly, the purpose of this study was twofold. Firstly, given
the associations between central adiposity and the development of
T2D (1, 2, 11), we examined the glucose-lowering potential of a low
volume, ready-to-drink WP shot innovated specifically as a non-
pharmaceutical agent for PPG control in centrally obese adult
males. Secondly, we assessed the practical application of our novel
WP shot, and examined the hormonal and gastrointestinal
responses to its ingestion in obese and healthy states.
METHODS
Participants
Adult male volunteers aged between 18 and 65 y were recruited
from the North-East of England. All participants regularly
consumed breakfast, adhered to a standard sleep–wake cycle,
Abbreviations: AUC, area under the curve; CVD, cardiovascular disease; DPP-IV,
dipeptidyl peptidase IV; GIP, Glucose-dependent insulinotropic polypeptide;
GLP-1, Glucagon-like peptide 1; iAUC, incremental area under the curve; NGT,
normal glucose tolerance; PPG, postprandial glycaemia; T2D, type 2 diabetes; WP,
whey protein.
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were non-smokers, free from metabolic disease and reported no
known food or dietary intolerances. Based upon the World
Health Organisation’s threshold associated with the greatest
risk of metabolic complications within Europid males, central
adiposity was determined if an individual presented with a
waist circumference of ≥102 cm or had a BMI ≥30 kg/m2 (32).
Further, physically active individuals with a BMI ranging
between 18.9 and 24.9 kg/m2 or a waist circumference of
≤94 cm were recruited as healthy controls (32). Ethical
approval granted by the Ethics Committee of the Faculty of
Medical Sciences, Newcastle University, and written informed
consent was obtained from all participants at least 72 h
prior to study enrolment. The trial was registered at
ISRCTN.com (ISRCTN95281775).
Study Design
Participants were entered into a randomised-control,
counterbalanced, crossover design involving two laboratory-
based feeding trials. Participants consumed a WP or control
[PLA] beverage 10 min before a standardised breakfast and
provided venous blood samples over a 240 min postprandial
period. Experimental visits were separated by 5–10 d.
Pre-Laboratory Control
Strenuous bouts of physical activity and alcohol were to be
avoided 24 and 48 h prior to each experimental visit,
respectively. Participants were instructed to avoid taking
analgesics containing paracetamol the day preceding entry to
the laboratory. Habitual dietary intake was recorded 24 h prior to
participant’s first mixed-meal tolerance test and was replicated
prior to the subsequent trial. A standardised evening meal
(897 kcal [3,753 kJ]: 58% carbohydrates, 23% fat, 19% protein)
was provided to be consumed the evening prior (~1,900–2,100 h)
to entering the laboratory.
Mixed Meal Tolerance Test
Participants reported to the laboratory following a ~12 h
overnight fast (0800 h ± 1 h). Once rested, an intravenous
cannula (B Braun, Germany) was introduced into an
antecubital vein for repeated blood sampling and a fasting
sample collected (t = −15 min). Ten minutes prior to a mixed-
nutrient breakfast (t = −10 min), participants randomly
consumed a WP shot (15.6 g protein; Lacprodan® DI-6820,
Arla Foods Ingredients Group P/S, Denmark) or volume-
matched water [100 ml; PLA]. The mixed-nutrient breakfast
consisted of 60 g ready-to-eat cereal (Cheerio’s, Nestle, UK) and
250 ml whole milk, providing each participant with 387 kcal
(1,619 kJ) of energy derived from 58% carbohydrates, 27% fat,
and 15% protein. The breakfast meal was initiated at t = −0 min
and was to be consumed within 15 min to standardise any effects
of eating rate on postprandial hormonal responses. Postprandial
venous blood samples, and subjective appetite parameters via
completion of a paper-based visual analogue scale [VAS], were
collected periodically over a 240 min postprandial period (t = 0–
240 min).
For the assessment of gastric emptying, participants were
provided with 100 ml water and 1,500 mg of paracetamol (Bristol
Laboratories Ltd, United Kingdom) that was consumed orally at
the commencement of breakfast. Orally administered
acetaminophen (paracetamol) is poorly absorbed by the
stomach but is rapidly absorbed within the small intestine;
thus, gastric emptying is the rate-limiting step for the
appearance of acetaminophen within blood (33). The time to
reach maximum acetaminophen concentrations occurs ~30–60
min post-ingestion; therefore, area under the curve during the
first 60 min [AUC0–60] is regarded as a marker of the velocity of
gastric emptying rates.
Water consumption during the postprandial period was
limited to 250 ml per trial. To control for postural changes in
plasma volume, participants remained seated throughout the
testing period. Pre-arranged transportation to the facilities was
provided to reduce pre-trial physical exertion.
Whey Protein Beverage
Participants were provided with a protein-rich, low volume,
ready-to-drink WP shot of low viscosity liquid (15.6 g of WP
in 100 ml). The pre-meal shot utilised a hydrolysed WP
ingredient (Lacprodan® DI-6820, Arla Food Ingredients Group
P/S) to produce a palatable, ready-to-drink beverage with a shelf
life of 6 months that was stable at both room temperature and
chilled environmental conditions. The design of this pre-meal
shot was an academic-industry collaboration that incorporated
the maximum dose of WP available to be present in minimal
liquid volume, whilst taking into consideration the energy
associated (100 kcal [418 kJ]), taste and mouthfeel of the WP
product, and consumer convenience and preference. Each
participant was provided with a “cocoa–cappuccino” flavoured
WP shot and assessed the preload’s palatability via completion of
a VAS. Please see supplementary data for detailed product
development information (Supplementary Material 1).
Blood Collection and Analytical Procedures
Venous whole blood samples were collected into EDTA and
serum vacutainers (Becton Dickinson, USA), and FC Mix
vacuettes (Greiner Bio-One, Austria). EDTA vacutainers were
pre-treated with aprotinin (#A6279, Sigma Aldrich, USA) and a
DPP-IV inhibitor (#DPP4-010, Merck Millipore, USA) for the
preservation of active GLP-1 [GLP-1ACTIVE] and kept on ice.
EDTA and serum vacutainers were centrifuged at 3,000 rpm at
4°C for 10 min with the corresponding plasma and serum
supernatant transferred into aliquots and stored at −80°C until
subsequent analysis.
Serum insulin concentrations were quantified using an ELISA
with <0.01% cross-reactivity with C-peptide or Proinsulin, and
an assay sensitivity of 6 pmol/L (intra-assay, 3.8%; inter-assay,
9.7%; #10-1113-01, Mercodia AB, Sweden).
Plasma GLP-1 were quantified using a C-terminal targeting
ELISA that measured the amidated forms of GLP-1, with a
sensitivity of 1.5 pmol/L (intra-assay, 5%; inter-assay, 6.4%;
#EZGLP1T-36K, Merck Millipore). This measurement reflects
both the total amount of GLP-1 secreted (herein referred to as
“GLP-1”) but also the peptide’s biological actions given GLP-1
activates afferent sensory neurons in the gastrointestinal tract
before being degraded in the capillaries of the gut (34).
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GLP-1ACTIVE was measured using an ELISA employing N-
terminal and side-viewing antibodies that measured GLP-1[7–36]
NH2 with no cross-reactivity with GLP-1[7–37], the primary GLP-1
metabolite (GLP-1[9–36] NH2/[9–37]), or N-terminally extended
forms (intra-assay, 10.3%; inter-assay, 14.1%; #80-GP1A-CH01,
Alpco, USA). Plasma GIP were analysed using a C-terminal
targeting ELISA that measured both the GIP[1–42] and GIP[3–42]
moiety with an assay sensitivity of 1 pmol/L (intra-assay, 3.3%;
inter-assay, 11.3%; #EZHGIP-54K, Merck Millipore).
HDL cholesterol, total cholesterol and fasting triglyceride
concentrations were determined using plasma on an
automated benchtop analyser (Reflotron Plus, Roche
Diagnostics, USA) with an intra-analyte variation of <2.6, <5.6
and <8.1%, respectively. Plasma glucose concentrations were
calculated from venous whole blood collected in FC Mix
vacuettes (intra-assay, 5.7%; Biosen C_Line, EKF Diagnostics,
UK). Serum acetaminophen concentrations were analysed using
a clinical analyser (Roche Cobas, Roche Diagnostics GmBH,
Germany) with a detection limit of 7.94mol/L (#05841208,
Roche Diagnostics GmBH). Acetaminophen measures were
conducted by the Blood Science unit of the Royal Victoria
Infirmary (Newcastle upon Tyne Hospitals, UK). Where
possible, samples from each participant were analysed on the
same assay plate.
Calculations
Total and incremental areas under the curve [AUCn and iAUCn,
respectively] were calculated using the trapezoidal rule (35) and
divided by the duration of the observational period of interest
(i.e., 60 or 240 min) to provide time-averaged values. The iAUC
included all area below the concentration curve, ignoring values
below baseline concentrations (35). HOMA-IR, which best
reflects hepatic insulin resistance, was calculated using basal
glucose and insulin concentrations from both mixed meal
tolerance tests (36). Subjective appetite parameters (fullness,
hunger, satisfaction, and prospective food intake) from the
paper-based VAS were combined to produce a combined-
appetite score (37). Missing sample points (1 time point from
one lean and one centrally obese participant during the PLA and
WP trial, respectively) were imputed by linear interpolation.
Sample Size Calculation
A sample size calculation was performed based on prior data
collected from our laboratory using PPG AUC as the primary
outcome (19, 24). To detect a statistical difference in PPG AUC,
12 participants were required in each group to test the null
hypothesis that the population means of both groups are equal
with probability of 0.8 and an associated type 1 error of 0.05.
Data Analysis
All data was assessed for normal distribution by a Shapiro–Wilks
test and investigation of boxplots for outliers. Non-parametric
data was log transformed and re-assessed for distribution. Where
transformation failed, data were assessed non-parametrically.
Between-group baseline variables were analysed by an
independent samples t test or a Mann–Whitney U test. A
mixed-model ANOVA with repeated measures with two
within-group (time and treatment [i.e., WP or PLA]) and one
between-group factors (condition [i.e., lean or centrally obese])
was performed to assess time-course changes in acetaminophen,
glucose, insulin, the incretin peptides, and subjective appetite.
AUC and iAUC variables (acetaminophen, hormonal, and
subjective appetite) were analysed by a two-way mixed
ANOVA with treatment and condition as factors. Post hoc
analysis, adjusted for multiple comparisons by Bonferroni
correction, were performed if ANOVAs revealed any
significant interaction effects. Postprandial insulin and GLP-
1ACTIVE concentrations were analysed by a two-way
Friedman’s rank test with pairwise comparison to locate
within-group treatment effects, and by a Kruskal–Wallis H test
to examine between-group differences during the two trials. The
Pearson product-moment correlation (r) and the Spearman’s
rank order correlation (rs) were used to explore associations
between variables displaying normal or non-normal distribution,
respectively. Inferential statistics was conducted using the
software package IBM SPSS Statistics (Version 26; IBM Corp.,
USA) and presented graphically using GraphPad Prism
(GraphPad software version 9.0, USA). Significance was set at
alpha p <0.05. All data is presented as means ± standard
deviation [SD] unless stated otherwise.
RESULTS
Participant Characteristics
The CONSORT [Consolidated Standards of Reporting Trials]
flow diagram is shown in Supplementary Material 2. Twenty-
five adult males (n = 12 centrally obese; n = 13 lean) were
recruited and completed this investigation. One lean individual
was highlighted as insulin-resistant (HOMA-IR 3.5) compared
to the rest of the lean cohort and was subsequently removed from
analysis. Therefore, data is analysed on 24 participants (n = 12
centrally obese; n = 12 lean). Participant characteristics are
presented in Table 1.
All subjects displayed normoglycemic fasting blood glucose
concentrations; however, fasting insulin concentrations were
markedly greater in the centrally obese cohort. Subsequently,
HOMA-IR scores were greater in centrally obese participants.
Fasting GLP-1 concentrations were also greater in this group.
However, relative to total GLP-1, centrally obese individuals had
lower GLP-1ACTIVE concentrations, indicative of increased
dipeptidyl-peptidase IV [DPP-IV] activity in the basal state.
When assessing participant characteristics individually, five
subjects from the centrally obese cohort displayed three or
more characteristics associated with the Metabolic Syndrome
(32). One centrally obese subject had a family history of diabetes.
Postprandial Responses
Plasma Glucose Concentrations
Fasting plasma glucose concentrations were similar on both study
days and did not differ between lean and centrally obese
participants. PPG displayed a significant time ∗ treatment
interaction (p <0.0001), such that PPG concentrations were
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reducedafterWPbetween t=15–45min (all p<0.05;Figures1A,B).
A significant time ∗ condition interaction (p = 0.020) was also
observed for PPG responses, where obese individuals displayed
greater PPG concentrations throughout the postprandial periods
compared to lean subjects (all p <0.05; see Figure 1A for specific
time points). A main effect of treatment for PPG AUC0–60 was
found (p <0.0001), whereby PPG AUC0–60 were 18.2 and 13%
lower following the WP shot compared to PLA in the lean and
TABLE 1 | Cohort characteristics.
Lean (n = 12) Centrally Obese (n = 12)
Characteristics
Age (years) 35.8 ± 10.6 34.8 ± 7.4
Stature (cm) 177.4 ± 5.3 181.5 ± 5.3
Body mass (kg) 74.7 ± 7.2 111.1 ± 12.1*
Body mass index (kg/m2) 23.7 ± 1.8 33.7 ± 2.4*
Waist circumference (cm) 80.4 ± 6.4 110.2 ± 10.1*
Hip circumference (cm) 95.4 ± 4.6 114.2 ± 10.8*
Waist-to-hip ratio 0.84 ± 0.04 0.97 ± 0.07*
SBP (mmHg) 118 ± 9.3 134.4 ± 8.6*
DBP (mmHg) 70.7 ± 6.8 81.3 ± 7.9*
Fasting Metabolic Variables
Fasting glucose (mmol/L) 4.40 ± 0.26 4.56 ± 0.4
Fasting insulin (pmol/L) 51.58 ± 17.14 101.94 ± 45.41*
HOMA-IR 1.68 ± 0.56 3.40 ± 1.40*
GLP-1 (pmol/L) 17.29 ± 4.63 25.78 ± 9.24*
GLP-1ACTIVE (pmol/L) 0.79 ± 0.40 0.78 ± 0.53
GLP-1ACTIVE/TOTAL (pmol/L) 0.05 ± 0.03 0.03 ± 0.02*
GIP (pmol/L) 11.01 ± 5.60 11.42 ± 4.67
TC (mmol/L) 4.22 ± 0.85 3.85 ± 0.66
HDL (mmol/L) 1.21 ± 0.27 0.95 ± 0.10*
Tg (mmol/L) 1.15 ± 0.24 1.60 ± 0.37*
DBP, diastolic blood pressure; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; HDL, high-density lipoprotein; HOMA-IR, homeostatic model
assessment—insulin resistance; SBP, systolic blood pressure; TC, total cholesterol; Tg, triglycerides.
Data presented are mean averages from duplicate measurements taken during both trials. Lipid markers were measured from each participant’s first trial.
All data is presented as mean ± SD.
*Denotes a statistical significance between groups as determined by an independent samples t test or a Mann–Whitney U Test (p <0.05).
A B
DC
FIGURE 1 | Mean ± SD time-course changes in plasma glucose (A, B) and insulin (C, D), following pre-meal consumption of a WP (red) and PLA preload (black) in
lean (A, C) and centrally obese (B, D) males. Pre-meal treatments were administered 10 min before breakfast (t = −10 min), as indicated by the arrow on the figure.
The mixed-nutrient meal was served at t = −0min and was to be consumed within 15 min. Time-course glucose data were analysed by a mixed-model ANOVA with
repeated measures (time and treatment). Time-course insulin data were analysed by a Friedman’s ranks test with pairwise comparison. Between-group differences in
postprandial insulin were assessed by a Kruskal–Wallis H test. *Denotes a within-group treatment effect (i.e., WP vs PLA). #denotes between-group differences (i.e.,
lean vs centrally obese) during the WP trial. ∇denotes between-group differences during the PLA trial. Statistical significance was accepted as p <0.05.
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centrally obese cohort, respectively (both p = 0.001; Table 2).
Compared to lean subjects, AUC0–60 were ~17% greater in
centrally obese subjects (condition, p = 0.002; Table 2). PPG
AUC0–240 were unaffected by the WP preload.
Plasma Insulin Concentrations
Due to the distribution of data, temporal insulin responses were
analysed non-parametrically. During both study days, insulin
concentrations increased following breakfast, peaking at t = 15–30
min before returning to baseline values (Figures 1C, D). In obese
subjects, insulin concentrations were greater at t = 0 min and at t =
120 min following the WP preload compared to PLA. Similarly, the
WP shot increased the early (t = −0 min and t = 0 min) and late (t =
90 min) secretion of insulin in lean subjects compared to PLA (all p
<0.016, Figures 1C, D). Overall insulin secretion (iAUC0–240) was
greater following the WP shot comparative to PLA (treatment, p =
0.047), although upon sub-group analysis, this was only evident in
the obese cohort (p = 0.044) and not lean subjects (p = 0.393). As
expected with the population studied, centrally obese individuals
had greater insulin concentrations during both trials (p <0.0001).
Accordingly, insulin iAUC0–240 were a ~two-threefold greater in
obese participants compared to lean during both trials (p
<0.0001; Table 2).
Plasma Total and Active GLP-1 Concentrations
GLP-1 concentrations increased following breakfast consumption
on both study days, peaking at t = 15 min before returning to
baseline values (Figures 2A, B). Compared to PLA, pre-meal WP
increased postprandial GLP-1 concentrations (time ∗ treatment, p
<0.0001) with significant differences between t = 0–120 min in
both groups (all p <0.034). Postprandial GLP-1 responses were
similar between cohorts (time ∗ condition, p = 0.577), although
overall GLP-1 concentrations were ~25% greater in obese
individuals (condition, p = 0.035). When assessing GLP-1
secretion (i.e., iAUC0–240), a significant main effect for treatment
was found (p = 0.002), such that WP increased GLP-1 iAUC0–240
by a two–three-fold compared to the PLA trial in both lean and
obese cohorts (p = 0.002 and p = 0.015, respectively). However,
GLP-1 secretion in response to the preloads differed between
groups (treatment ∗ condition, p = 0.011). During the WP trial,
GLP-1 iAUC0–240 was ~27% lower in centrally obese participants
compared to the lean (p = 0.001); whereas GLP-1 iAUC0–240 were
similar between groups during PLA (p = 0.760; Table 2).
As expected from the increase in GLP-1, postprandial GLP-
1ACTIVE concentrations were elevated during the WP trial
compared to PLA (p <0.0001) with significant differences at t
= 0 min and between t = 30–120 min in both groups (all p
<0.034; Figures 2C, D). Accordingly, GLP-1ACTIVE iAUC0-240
was increased by a two-threefold during the WP trial compared
to PLA (treatment, p <0.0001; Table 2). A significant treatment ∗
condition interaction was also found (p = 0.043), which revealed
that during the WP trial there was a tendency for GLP-1ACTIVE
iAUC0–240 to be lower in obese subjects compared to lean (p =
0.085), with no differences during PLA (p = 0.671).
TABLE 2 | Postprandial area under the curve values of biochemical parameters during the mixed-meal tolerance test.
Lean (n = 12) Centrally Obese (n = 12) P-value
WP PLA WP PLA Treatment Condition Treatment*Condition
Glucose AUC (mmol/L/min−1)a
0–60 min 3.8 ± 0.5 4.7 ± 0.7* 4.6 ± 0.4# 5.3 ± 0.6*# P <0.0001 P = 0.002 P = 0.468
0–240 min 3.9 ± 0.4 4.0 ± 0.4 4.4 ± 0.3# 4.5 ± 0.3# P = 0.055 P <0.0001 P = 0.715
Insulin iAUC (pmol/L/min−1)a
0–60 min 97.0 ± 59.4 102.4 ± 59.9 361.8 ± 226.4# 311.1 ± 215.5# P = 0.440 P <0.0001 P = 0.353
0–240 min 35.1 ± 20.0 30.81 ± 18.1 139.5 ± 90.2# 83.3 ± 54.6*# P = 0.047 P <0.0001 P = 0.379
GLP-1 iAUC (pmol/L/min−1)a
0–60 min 23.6 ± 7.4 7.3 ± 5.0* 19.4 ± 7.9 6.7 ± 4.0* P <0.0001 P = 0.217 P = 0.181
0–240 min 15.0 ± 4.3 4.7 ± 3.7* 11.8 ± 4.6# 5.2 ± 4.1* P = 0.001 P = 0.040 P = 0.011
GLP-1ACTIVE iAUC (pmol/L/min
−1)a
0–60 min 3.8 ± 1.9 1.5 ± 1.1* 2.3 ± 1.4 1.1 ± 0.6* P <0.0001 P = 0.196 P = 0.217
0–240 min 2.0 ± 0.7 0.7 ± 0.4* 1.4 ± 0.7 0.8 ± 0.5* P <0.0001 P=0.426 P = 0.043
GLP-1ACTIVE/TOTAL iAUC (pmol/L × min
−1)b
0–60 min 4.7 ± 2.6 2.5 ± 1.7* 2.4 ± 1.7# 1.9 ± 1.4 P = 0.009 P=0.021 P = 0.099
0–240 min 10.2 ± 6.4 5.2 ± 3.6* 7.1 ± 3.8 5.4 ± 4.7 P = 0.004 P = 0.386 P = 0.132
GIP iAUC (pmol/L/min−1)a
0–60 min 50.5 ± 19.0 51.8 ± 16.2 57.9 ± 23.0 53.9 ± 23.2 P = 0.650 P = 0.549 P = 0.383
0–240 min 36.5 ± 14.8 31.2 ± 13.7 43.3 ± 14.9 33.8 ± 13.7* P <0.0001 P = 0.382 P = 0.247
Acetaminophen AUC (mol/L/min-1)a
0-60min 65.1 ± 32.5 100.7 ± 31.1* 58.1 ± 19.7 90.0 ± 20.3* P <0.0001 P = 0.307 P = 0.787
0-240min 68.8 ± 14.9 77.5 ± 17.5 60.3 ± 13.1 67.2 ± 11.4 P = 0.029 P = 0.067 P = 0.793
Data presented as means ± SD.
aVariables are presented as time-averaged during the early (0 -60 min) and total (0–240 min) postprandial period.
bThe iAUC for GLP-1ACTIVE/TOTAL is presented as the as the sum of iAUC over time (i.e., 60 or 240 min) and is thus, not time-averaged.
All data were analysed by a two-way mixed ANOVA. Between and within group differences were analysed if there were any significant main or interaction effects reported from the ANOVA.
*Denotes a within-group treatment effect (WP vs PLA).
#Denotes a between-group effect (lean vs centrally obese).
Bold values indicate statistical significance from the two-way mixed ANOVA.
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Plasma GLP-1ACTIVE/TOTAL Concentrations
Relative to the total amount of GLP-1 secreted during the early
postprandial period (0–60 min), the GLP-1ACTIVE/TOTAL iAUC0–
60 was greater during the WP trial compared to PLA (treatment,
p = 0.009) with a tendency for similar responses between cohorts
(condition ∗ treatment, p = 0.099). However, when GLP-1ACTIVE/
TOTAL iAUC0–60 responses were assessed individually by pairwise
comparisons, such an effect was only evident in the lean cohort
(p = 0.004) and not in obese subjects (p = 0.431). Additionally, it
was revealed that the GLP-1ACTIVE/TOTAL iAUC0–60 during the
WP trial was lower in obese individuals compared to lean
participants (p = 0.016), whereas GLP-1ACTIVE/TOTAL iAUC0–60
were similar between cohorts during PLA (p = 0.329).
Plasma GIP Concentrations
Fasting GIP concentrations were ~23% lower at commencement
of the WP trial vs PLA in the centrally obese group (p = 0.040),
whereas basal GIP concentrations were similar between trials in
lean subjects (Figures 2E, F). During both study days, GIP
concentrations increased following the breakfast meal before
returning to baseline values at t = 240 min. Postprandial GIP
concentrations displayed a significant time ∗ treatment
interaction (p <0.0001). In obese subjects, GIP concentrations
were elevated at t = 0 min, t = 90 min and t = 120 min during the
WP trial compared to PLA (all p <0.001; Figure 2F). Similar
temporal responses were observed in the lean cohort but without
statistical significance (Figure 2E). GIP iAUC0–240 demonstrated
a significant treatment effect (p <0.0001), such that GIP
iAUC0–240 was greater during WP compared to PLA. Upon
sub-group analysis, GIP iAUC0–240 were increased by 17.7% in
the lean group and by 34.3% in the centrally obese group
following WP compared to PLA (p = 0.078 and p = 0.001,
respectively). GIP iAUC0-240 were similar between cohorts
during both study days (condition, p = 0.382; Table 2).
Gastric Emptying
Following breakfast, acetaminophen concentrations increased
and remained elevated throughout the trial (Figure 3). Serum
acetaminophen concentrations demonstrated a significant time ∗
treatment interaction (p <0.0001), such that acetaminophen
concentrations were lower between t = 0–45 min following WP
compared to PLA (p <0.0001). As such, acetaminophen AUC0–60
were ~35% lower during WP compared to PLA (treatment,
p <0.0001; Table 2). During both study days, gastric emptying
rates were similar between subjects. Using pooled data from all





FIGURE 2 | Mean ± SD time-course changes in plasma GLP-1 (A, B), GLP-1ACTIVE (C, D) and GIP (E, F) following pre-meal consumption of a WP (red) and PLA
preload (black) in lean (A, C, E) and centrally obese (B, D, F) males. Pre-meal treatments were administered 10 min before breakfast (t = −10 min), as indicated by
the arrow on the figure. The mixed-nutrient meal was served at t = −0 min and was to be consumed within 15 min. GLP-1 and GIP data were analysed by a mixed-
model ANOVA with repeated measures (time and treatment). Time-course GLP-1ACTIVE data were analysed by a Friedman’s ranks test with pairwise comparison to
locate within-group treatment effects, and by a Kruskal–Wallis H test to examine between-group differences. *Denotes a within-group treatment effect (p <0.05).
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acetaminophen AUC0–60 and glucose AUC0–60 was revealed (r =
0.318; p = 0.028).
Subjective Appetite
There were no differences in individual appetite components
following both WP and PLA treatments, thus only combined-
appetite scores were analysed. Combined-appetite scores
decreased following breakfast in both study days before
returning to baseline levels upon trial completion (time effect,
p <0.001). Combined-appetite scores were unaffected by the WP
treatment and displayed similar responses between lean and
obese participants (data not shown).
Metabolic Predictors for GLP-1 Secretion
Since there were differing GLP-1 responses following the WP
shot, we assessed potential metabolic predictors for GLP-1
secretion. While there were no correlates found for GLP-1
secretion during PLA (p >0.110), GLP-1 iAUC0–240 during the
WP trial was negatively correlated with waist-to-hip ratio (rs =
−0.431; p = 0.035) and fasting triglycerides (rs = −0.441; p =
0.031). Individuals with a greater HOMA-IR also had lower
GLP-1 iAUC0–240 following mealtime WP supplementation (rs =
−0.419; p = 0.042), but not during PLA. There were no predictors
for GIP secretion.
Preload Palatability and Gastrointestinal
Responses
Participants responded positively to the WP preload in terms of
taste (76.6 ± 12.4 mm), likability (73.7 ± 11.8 mm) and
palatability (77.6 ± 12.7 mm). There were no reported upper
or lower gastrointestinal side effects following WP consumption.
DISCUSSION
We examined the postprandial hormonal and metabolic responses
to a mixed-nutrient meal following consumption of novel, ready-
to-drink shot containing a low dose of WP (15 g) in lean and
centrally obese NGT males. Our primary finding was that
consumption of a small pre-meal WP beverage markedly
attenuates the rise in PPG in both lean and obese cohorts. These
reductions in PPG were associated with the early and sustained
secretion of GLP-1, and a slowing of gastric emptying. However,
despite comparable reductions in PPG, the metabolism and
secretion of GLP-1 following mealtime WP supplementation
differs between centrally obese and lean subjects, which may
derive from several metabolic complications associated with the
viscerally obese state. These data may have important implications
for nutritional strategies targeting the biological actions of GLP-1
in abdominally obese and insulin resistant patient populations.
The dose of WP provided, although ~25–65% smaller than
those used previously in non-patient populations (24, 38, 39),
sufficiently reduced PPG AUC0–60 (~13–18%) in both lean and
centrally obese adult males. Despite the marked reduction in
PPG, pre-meal WP supplementation had minimal effects on
insulin secretion across the early postprandial period, which
contrasts previous literature (19, 22, 23, 38), suggesting that the
observed reductions in PPG were largely insulin-independent.
Indeed, gastric emptying, which is a major determinant of PPG
(18, 40), was substantially delayed following the WP shot; the
latter would also favour the modest insulin responses found (41).
Of note, insulin concentrations were elevated immediately post-
breakfast (t = 0 min) during the WP trial, which may be in
response to an increase in plasma glucagon that can occur
following protein feeding (22, 23), although the effects of
insulin and glucagon on PPG appear counterbalanced (14).
Importantly, our WP shot was just as effective at reducing PPG
excursions in centrally obese individuals as it was for lean
subjects, which may have significance since our obese cohort
exhibited several features consistent with the Metabolic
Syndrome (32). For instance, for the same modest elevation in
PPG (~8 mmol/L), the incidence of T2D is increased by two-fold
in centrally obese individuals with features of the Metabolic
Syndrome compared to obese people with more favourable
metabolic characteristics (11). Fat accretion around central
areas is also associated with increased glycaemic variability
(25), which may induce oxidative stress and vascular injury
(42), facilitating the onset of CVD. Our data, therefore,
supports the application of a low dose of pre-meal WP to
regulate PPG in this clinically vulnerable cohort.
A B
FIGURE 3 | Mean ± SD time-course changes in serum acetaminophen concentrations following the WP (red) and PLA preload (black) in lean (A) and centrally
obese (B) males. Data were analysed by a mixed-model ANOVA with repeated measures (time and treatment). *Denotes a significant within-group treatment effect
(p <0.05).
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Remarkably, PPG concentrations remained largely
unchanged from basal values when the mixed-nutrient meal
was preceded by the pre-meal WP shot. The magnitude of this
suppression was surprising, which may be due to the NGT
populations studied, although mealtime WP supplementation
(~20 g) has previously failed to produce similar results in lean
(38) and obese (24) NGT adults. Additionally, despite
upholding NGT, our centrally obese cohort were significantly
insulin resistant and may have shown slight glucose intolerance
as indicated by the greater post-meal glucose excursions and
accompanying hyperinsulinemia compared to lean subjects
(43). It is, therefore, unlikely that these findings were due to
glycaemic status of our subjects. Of note, an acute dose of
exenatide markedly supressed the glycaemic responses to an
oral glucose load in centrally obese adults (44), akin to our
reported findings. The authors found that exenatide
substantially supressed endogenous glucose production
[EGP], increased hepatic glucose uptake, and delayed the
absorbance of oral glucose (44). Similar mechanisms were
also reported in lean adults following sequential glucose
loading (45). It is appealing to speculate that our WP preload
may have augmented similar gluco-regulatory pathways to
those described. In this regard, the increase in GLP-1
following the WP shot may be of particular importance since
GLP-1 can inhibit EGP and promote hepatic glucose uptake,
independent of its actions on pancreatic islet hormones
(46, 47). However, the influence of mealtime WP on hepatic
glucose metabolism remains to be characterised and requires
future investigation.
The consumption of the pre-meal WP shot differentially
affected the secretion of the incretin peptides compared to
PLA, such that the WP preload elicited a marked increase in
the release of GLP-1 (~127–218% iAUC0–240), whereas
postprandial GIP responses were modestly affected (~17–34%
iAUC0–240). This data suggests that GLP-1 plays a greater role in
PPG regulation following a low dose of pre-meal WP in NGT
adults. Indeed, this assertion is consistent with the observed
slowing of gastric emptying during the WP trial, which was most
likely mediated by GLP-1 (18, 48). In fact, GLP-1’s influence on
gastric emptying may outweigh its insulinotropic effects to
regulate PPG (49), where the glucose-lowering potency of
GLP-1 is attenuated when its actions to delay gastric emptying
are overridden (50). On the other hand, GIP reduces PPG by
augmenting insulin secretion in a strict glucose-dependent
manner (51). Thus, due to the low PPG concentrations
experienced during the WP trial, the “requirement” for the
insulinotropic actions of GIP was negligible, which may
provide an explanation for the modest postprandial GIP
responses observed (41).
In the present study, we confirm previous reports that GLP-1
secretion is disordered in obese individuals (27, 28), particularly
in those with abdominal adiposity (52). During the WP trial,
GLP-1 iAUC0–240 was ~27% lower in centrally obese
participants compared to their lean counterparts. However,
these findings were surprising given that there were no group
differences in GLP-1 secretion during PLA. Gastric emptying
rates, which are known to determine GLP-1 release (53), were
also similar between groups; although our chosen method to
quantify gastric emptying may have been inadequate to
distinguish inter-variable differences. Nonetheless, there is no
clear evidence to suggest that gastrointestinal motility is
disordered or unresponsive to dietary protein-mediated
stimulation in obese individuals (54, 55). Therefore, it is
unlikely that the reduced GLP-1 secretion observed during
the WP trial was due to delayed gastric emptying in centrally
obese subjects.
Obesity is associated with the reduced expression of specific
L-cell genes, including those associated with nutrient sensing
(56), which may provide an explanation for the diminished GLP-
1 secretory responses. Explorative analysis revealed that during
the WP trial, GLP-1 secretion was inversely related with an
individual’s fasting triglyceride concentrations (rs = −0.441) and
waist-to-hip ratio (rs = −0.431), whereas no correlates were
found during PLA. Insulin resistance was also associated with
attenuated GLP-1 responses following the WP shot (rs = −0.419).
Given GLP-1 secretion in response to a large dose of hydrolysed
WP (~48 g) appears to be intact in obese individuals (55), central
adiposity, or its associated metabolic derangements, may
compromise the responsiveness of protein-sensing receptors to
mediate GLP-1 secretion in response to smaller amounts of
dietary proteins/peptones (56, 57). It must be acknowledged
that this assertion, although of interest, does not establish a
causal relationship and requires future study.
In the current investigation, we measured both the total and
active GLP-1 peptide, providing conclusions on the metabolism
of GLP-1 following its release (34). As expected, GLP-1ACTIVE
concentrations were greater following the WP treatment, which
reflects the increase in the total peptide secreted. However, the
WP shot also increased the GLP-1ACTIVE/TOTAL ratio
suggesting an inhibitory effect on DPP-IV activity, although
this was only evident in the lean cohort. Thus, our WP dose
(15 g) may have been insufficient to inhibit DPP-IV activity in
centrally obese individuals, which is unsurprising given that
DPP-IV activity is elevated in obese states (58, 59). This
hypothesis is also coherent with previous findings in
overweight people with well controlled T2D, where an
increase in GLP-1ACTIVE/TOTAL was observed after
consumption of a WP preload at a dose three-fold greater
than what was administered here (15 g vs 50 g) (21).
Nonetheless, the physiological importance of this observation
is unclear, particularly given WP reduced PPG in both cohorts,
implying that the mechanisms by which mealtimeWP regulates
glycaemia are at least partially intact in abdominally obese
individuals. The regulation of PPG by endogenous GLP-1 is
also complex that involves the activation of vagal afferent fibres
in the gut, prior to its release and degradation (34), that are not
reflected by our venous measures. To challenge this concept
and to delineate the therapeutic role WP-mediated GLP-1
secretion on PPG metabolism, it would be worthwhile to
examine the application of mealtime WP with and without
the concomitant administration of a DPP-IV inhibitor and the
GLP-1 antagonist, exendin (9–39) NH2.
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In both cohorts, subjective appetite parameters were
unaffected following the WP preload, which is at variance
with some (19) but not all (24, 38) previous studies. These
results might be construed as surprising given the increase in
GLP-1 observed during the WP trial, where the consumption
of WP also stimulates the secretion of several other
anorexigenic hormones and supresses postprandial ghrelin
concentrations (60, 61). However, the physiological and
hormonal changes that result in objective reductions in
energy intake are not always noticeable at the subjective level
(62). It is, therefore, difficult to conjecture from the subjective
markers reported the potential effect of our pre-meal WP shot
on subsequent energy intake.
There are few studies that have assessed the long-term
application of mealtime WP to regulate glycaemia, which
may be in part due to the laborious and inconvenience
associated with preparing traditional WP supplements,
particularly if these are to be consumed multiple times per
day (14). Novel to this study, we used a WP preload created
specifically for free-living glycaemic management. Our WP
shot contained 15 g of dietary protein from 100 ml of low-
viscosity liquid that was importantly both effective in its actions
but also highly palatable and convenient in its delivery. The WP
preload was presented in contemporary packaging and was
served “ready-to-drink”, which has been previously shown to
attenuate patient self-consciousness when consuming protein
supplements publicly (30). Additionally, the WP shot had a ~6-
month shelf-life that, without compromising peptide stability
and functionality, was stable at both chilled and at room
temperatures. This allows for unrestricted access without the
need for immediate refrigeration and may help facilitate
mealtime WP’s application in a real-world setting. Further
strengthening the ecological validity of our findings, care was
taken to provide a commonly consumed breakfast meal, and
administering the WP shot as a 10 min preload was a timing
that we considered to embody free-living eating patterns.
There are, however, several limitations to this study that
merit comment. Firstly, the acetaminophen absorbance test
was used to measure gastric emptying, which cannot
discriminate between the emptying of liquids or solids and
fails to distinguish between the effects of gastric emptying or
those from small intestinal glucose absorbance. Nonetheless,
our finding agrees with previous interventions that used the
gold standard, scintigraphy, to measure gastric emptying
following mealtime WP supplementation (20). Secondly,
since our assessments were carried out at a single breakfast
meal, our reported findings do not represent the glycaemic and
hormonal responses that occur at meals consumed later in the
day (63). To the best of the authors’ knowledge, no studies to
date have examined the effect of circadian rhythm on the
application of mealtime WP, which requires future
investigation. Finally, we did not assess the application of
pre-meal WP on hepatic glucose metabolism or trace PPG
fluxes. This would have provided detailed insight into the
influence of our small WP preload on PPG metabolism,
particularly since the ingestion of WP stimulates glucagon
secretion (22) that may counterintuitively affect EGP in
insulin-resistant individuals.
In summary, consuming 15 g of dietary protein from a
small, contemporary WP shot diminishes PPG excursions in
lean and centrally obese males. Providing a WP beverage in a
small, ready-to-drink format that encompasses both
consumer convenience and preference may be a suitable way
to apply this strategy free-living. However, the metabolism
and se c r e t i on o f GLP-1 fo l l ow ing mea l t ime WP
supplementation is compromised in centrally obese patients,
which requires consideration when applying this novel
strategy in abdominally obese individuals. Whether such
defects are associated with an individual’s insulin resistance,
their obese state or other visceral adiposity-related ailments
is unknown.
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